Literature DB >> 19508861

The heterogenous nuclear riboprotein S1-1 regulates AT1 receptor gene expression via transcriptional and posttranscriptional mechanisms.

Cornelius F H Mueller1, Anja Berger, Sebastian Zimmer, Vedat Tiyerili, Georg Nickenig.   

Abstract

The AT1 receptor plays an essential role in the pathogenesis of atherosclerosis. AT1 receptor expression is predominately mediated via mRNA destabilization by mRNA binding proteins. We identified via MALDI-analysis the heterogenous nuclear riboprotein S1-1 as an important regulator of AT1 receptor mRNA stability. The S1-1 protein possesses multiple nucleolar and cellular functions in vascular smooth muscle cells (VSMC). Overexpression of S1-1 sense resulted in VSMC in significant stabilization of AT1 receptor mRNA. However, this stabilization of the AT1 receptor mRNA is accompanied by a significantly reduced AT1 receptor mRNA transcription as shown via nuclear run-on assay resulting finally in reduced AT1 receptor mRNA levels. Additionally, S1-1 overexpression leads to increased apoptosis in VSMC and decreases VSMC proliferation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19508861     DOI: 10.1016/j.abb.2009.06.002

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  14 in total

1.  Differential downregulation of Rbm5 and Rbm10 during skeletal and cardiac differentiation.

Authors:  Julie J Loiselle; Leslie C Sutherland
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-11-01       Impact factor: 2.416

Review 2.  RNA binding proteins in the regulation of heart development.

Authors:  Yotam Blech-Hermoni; Andrea N Ladd
Journal:  Int J Biochem Cell Biol       Date:  2013-08-20       Impact factor: 5.085

3.  The role of RBM10 mutations in the development, treatment, and prognosis of lung adenocarcinoma.

Authors:  Zhenqing Li; Qun Xue; Jianxun Xu; Pengfei Zhang; Bo Ding
Journal:  Cell Cycle       Date:  2020-10-16       Impact factor: 4.534

4.  Insight into the role of alternative splicing within the RBM10v1 exon 10 tandem donor site.

Authors:  Sarah J Tessier; Julie J Loiselle; Anne McBain; Celine Pullen; Benjamin W Koenderink; Justin G Roy; Leslie C Sutherland
Journal:  BMC Res Notes       Date:  2015-02-19

5.  RBM5 reduces small cell lung cancer growth, increases cisplatin sensitivity and regulates key transformation-associated pathways.

Authors:  Julie J Loiselle; Justin G Roy; Leslie C Sutherland
Journal:  Heliyon       Date:  2016-11-29

6.  Splicing arrays reveal novel RBM10 targets, including SMN2 pre-mRNA.

Authors:  Leslie C Sutherland; Philippe Thibault; Mathieu Durand; Elvy Lapointe; Jose M Knee; Ariane Beauvais; Irina Kalatskaya; Sarah C Hunt; Julie J Loiselle; Justin G Roy; Sarah J Tessier; Gustavo Ybazeta; Lincoln Stein; Rashmi Kothary; Roscoe Klinck; Benoit Chabot
Journal:  BMC Mol Biol       Date:  2017-07-20       Impact factor: 2.946

7.  RBM10 promotes transformation-associated processes in small cell lung cancer and is directly regulated by RBM5.

Authors:  Julie J Loiselle; Justin G Roy; Leslie C Sutherland
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

Review 8.  RBM10: Harmful or helpful-many factors to consider.

Authors:  Julie J Loiselle; Leslie C Sutherland
Journal:  J Cell Biochem       Date:  2018-01-19       Impact factor: 4.429

9.  RBM10 Modulates Apoptosis and Influences TNF-α Gene Expression.

Authors:  Ke Wang; Mackensey L Bacon; Julie J Tessier; Nina D Rintala-Maki; Vanessa Tang; Leslie C Sutherland
Journal:  J Cell Death       Date:  2012-01-27

10.  Post-transcriptional regulation of Rbm5 expression in undifferentiated H9c2 myoblasts.

Authors:  Julie J Loiselle; Sarah J Tessier; Leslie C Sutherland
Journal:  In Vitro Cell Dev Biol Anim       Date:  2015-12-10       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.